Embecta Faces Lawsuit After Stock Plummets 57%

Embecta, a company known for its insulin pen needles, is in hot water after its stock took a nosedive by over 57%. The dramatic drop happened because they allegedly misled investors about how well their insulin pen needle products were doing, leading to a securities fraud class action lawsuit. This all came to light after their disappointing Q2 2026 results. What does it mean for you? If you're an Embecta investor, this could be your moment to step up and join the lawsuit to potentially recover some losses. For everyone else, it's a reminder to keep a close eye on where you put your money and to do your homework on company claims.